Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + enfortumab vedotin
- Development stage
- Preclinical
- Lead developer
- Astellas Pharma
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Atezolizumab + enfortumab vedotin is a combination therapy consisting of **atezolizumab**, a monoclonal antibody immune checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1), and **enfortumab vedotin**, an antibody-drug conjugate (ADC) targeting Nectin-4 with a monomethyl auristatin E (MMAE) cytotoxic payload. Atezolizumab inhibits the PD-L1/PD-1 pathway, thereby potentiating T-cell mediated antitumor immune responses. Enfortumab vedotin binds to Nectin-4 on tumor cells, is internalized, and releases MMAE to disrupt microtubules and induce apoptosis. The combination aims to enhance antitumor immunity and direct cytotoxicity, and is under investigation for advanced urothelial carcinoma[2][3][4].
- Other names
- atezolizumab + enfortumab vedotinatezolizumab/enfortumab vedotin combination
02
Targets
TUBB (Tubulin (alpha and beta subunits))PVRL4 (Nectin cell adhesion molecule 4)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on atezolizumab + enfortumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + enfortumab vedotin.